MX2016009499A - Antagonista de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. - Google Patents
Antagonista de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita.Info
- Publication number
- MX2016009499A MX2016009499A MX2016009499A MX2016009499A MX2016009499A MX 2016009499 A MX2016009499 A MX 2016009499A MX 2016009499 A MX2016009499 A MX 2016009499A MX 2016009499 A MX2016009499 A MX 2016009499A MX 2016009499 A MX2016009499 A MX 2016009499A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- treatment
- crf1 receptor
- adrenal hyperplasia
- congenital adrenal
- Prior art date
Links
- 108091005471 CRHR1 Proteins 0.000 title abstract 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 238000010606 normalization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Antagonistas de receptor de CRF1 tienen el potencial para inhibir directamente liberación de ACTH en pacientes con CAH y por lo mismo permitir normalización de producción de andrógenos mientras que se usan dosis menores, más fisiológicas de hidrocortisona, y de esta forma reduciendo efectos laterales asociados a tratamiento.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461929941P | 2014-01-21 | 2014-01-21 | |
US201461981033P | 2014-04-17 | 2014-04-17 | |
US201462069155P | 2014-10-27 | 2014-10-27 | |
PCT/US2015/012315 WO2015112642A1 (en) | 2014-01-21 | 2015-01-21 | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009499A true MX2016009499A (es) | 2017-02-27 |
Family
ID=52450623
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009499A MX2016009499A (es) | 2014-01-21 | 2015-01-21 | Antagonista de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
MX2021012539A MX2021012539A (es) | 2014-01-21 | 2016-07-21 | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
MX2022000080A MX2022000080A (es) | 2014-01-21 | 2016-07-21 | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012539A MX2021012539A (es) | 2014-01-21 | 2016-07-21 | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
MX2022000080A MX2022000080A (es) | 2014-01-21 | 2016-07-21 | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
Country Status (13)
Country | Link |
---|---|
US (5) | US20170020877A1 (es) |
EP (1) | EP3096756A1 (es) |
JP (4) | JP6585625B2 (es) |
KR (2) | KR20210064407A (es) |
CN (2) | CN111228274A (es) |
AU (3) | AU2015209452C1 (es) |
BR (1) | BR112016016975B1 (es) |
CA (2) | CA3155599A1 (es) |
IL (4) | IL296683B2 (es) |
MX (3) | MX2016009499A (es) |
NZ (1) | NZ722122A (es) |
RU (1) | RU2718918C2 (es) |
WO (1) | WO2015112642A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11951112B2 (en) | 2021-04-12 | 2024-04-09 | Maxim Masiutin | Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3096756A1 (en) | 2014-01-21 | 2016-11-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
EP3107569A4 (en) | 2014-02-20 | 2018-02-21 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
CN109906222B (zh) | 2016-09-07 | 2023-08-01 | 加利福尼亚大学董事会 | 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂 |
KR20200040761A (ko) * | 2017-08-14 | 2020-04-20 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
JP7427655B2 (ja) * | 2018-04-27 | 2024-02-05 | スプルース バイオサイエンシーズ,インク. | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 |
JP2022000473A (ja) * | 2018-12-07 | 2022-01-04 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト、その医薬製剤および固体形態 |
AU2019393256A1 (en) * | 2018-12-07 | 2021-07-29 | Neurocrine Biosciences, Inc. | CRF1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
EP3986416A4 (en) * | 2019-07-19 | 2023-06-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
WO2021062246A1 (en) * | 2019-09-27 | 2021-04-01 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
JP2023531164A (ja) * | 2020-06-10 | 2023-07-21 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト |
CA3188730A1 (en) | 2020-08-12 | 2022-02-17 | Christopher Barnes | Methods and compositions for treating polycystic ovary syndrome |
US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4949582B1 (es) | 1969-01-20 | 1974-12-27 | ||
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
US6664261B2 (en) | 1996-02-07 | 2003-12-16 | Neurocrine Biosciences, Inc. | Pyrazolopyrimidines as CRF receptor antagonists |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
ATE213495T1 (de) | 1996-09-16 | 2002-03-15 | Du Pont Pharm Co | Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper |
FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US6482836B1 (en) | 1997-04-22 | 2002-11-19 | Charles Huang | CRF antagonistic quino- and quinazolines |
EP0937081A1 (en) | 1997-08-22 | 1999-08-25 | Du Pont Pharmaceuticals Company | NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS |
US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
CA2369553A1 (en) | 1999-04-02 | 2000-10-12 | Raymond F. Horvath | N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators |
FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
FR2802530B1 (fr) | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
US7276526B2 (en) | 2001-07-13 | 2007-10-02 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
JP2007522200A (ja) | 2004-02-13 | 2007-08-09 | ファイザー・プロダクツ・インク | 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ |
JP2008509933A (ja) | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
WO2006044821A1 (en) | 2004-10-19 | 2006-04-27 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
ATE424402T1 (de) | 2005-03-21 | 2009-03-15 | Lilly Co Eli | Imidazopyridinverbindungen |
US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
US20090234117A1 (en) | 2005-05-27 | 2009-09-17 | Toshihiko Kashiwagi | Pyrazolopyrimidine Derivative |
EP1957056A2 (en) | 2005-11-10 | 2008-08-20 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
JPWO2007069565A1 (ja) | 2005-12-12 | 2009-05-21 | 小野薬品工業株式会社 | 二環式複素環化合物 |
WO2007069671A1 (ja) | 2005-12-15 | 2007-06-21 | Ono Pharmaceutical Co., Ltd. | 二環式複素環化合物 |
US8153127B2 (en) | 2006-02-07 | 2012-04-10 | Phenoquest Ag | Method of treating depression |
EP1834641A1 (en) | 2006-03-16 | 2007-09-19 | Sanofi-Aventis | Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia |
JP2009538331A (ja) | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 抑うつ障害のための治療 |
MX2009003125A (es) * | 2006-09-20 | 2009-05-28 | Lilly Co Eli | Tiazol pirazolopirimidinas como antagonistas de receptor de crf1. |
CA2662000C (en) | 2006-09-20 | 2013-01-08 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
JP2010507664A (ja) | 2006-10-25 | 2010-03-11 | 武田薬品工業株式会社 | ベンズイミダゾール化合物 |
JP2010514672A (ja) | 2006-12-29 | 2010-05-06 | 武田薬品工業株式会社 | Crfアンタゴニスト活性を有する縮合複素環化合物 |
WO2008083070A1 (en) | 2006-12-29 | 2008-07-10 | Neurogen Corporation | Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties |
TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
WO2009008552A1 (en) | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
WO2009144632A1 (en) | 2008-05-30 | 2009-12-03 | Pfizer Limited | Novel compounds |
US7932256B2 (en) | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
WO2010014687A1 (en) | 2008-07-31 | 2010-02-04 | Bristol-Myers Squibb Company | Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity |
US7994203B2 (en) | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
BRPI0920113A2 (pt) | 2008-11-03 | 2020-08-11 | Synthes Gmbh | conjunto de haste ajustável |
WO2010096426A2 (en) | 2009-02-20 | 2010-08-26 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
HUP0900267A2 (en) | 2009-04-30 | 2011-03-28 | Sanofi Aventis | Process for preparing of thiazole amines and intermediates thereof |
WO2011043387A1 (ja) | 2009-10-08 | 2011-04-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロオキサゾール化合物 |
AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
CN104768555B (zh) | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
WO2013160317A2 (en) | 2012-04-23 | 2013-10-31 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
EP2841595A2 (en) * | 2012-04-23 | 2015-03-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Genetic predictors of response to treatment with crhr1 antagonists |
EP3096756A1 (en) * | 2014-01-21 | 2016-11-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
WO2016065177A1 (en) | 2014-10-22 | 2016-04-28 | The Trustees Of The University Of Pennsylvania | Method of treating depression and other stress related disorders |
EP3253752B1 (en) | 2015-02-06 | 2023-08-16 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
WO2016156576A1 (en) | 2015-04-02 | 2016-10-06 | Hmnc Value Gmbh | Method of treatment using genetic predictors of a response to treatment with crhr1 antagonists |
WO2018012066A1 (ja) * | 2016-07-14 | 2018-01-18 | 株式会社コナミデジタルエンタテインメント | ゲームシステム、端末装置及びプログラム |
WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
WO2018219804A1 (en) | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Self-microemulsifying drug delivery systems |
MX2019015318A (es) | 2017-08-14 | 2020-07-20 | Spruce Biosciences Inc | Antagonistas del receptor del factor liberador de corticotropina. |
KR20200040761A (ko) | 2017-08-14 | 2020-04-20 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
JP7427655B2 (ja) * | 2018-04-27 | 2024-02-05 | スプルース バイオサイエンシーズ,インク. | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 |
AU2019393256A1 (en) | 2018-12-07 | 2021-07-29 | Neurocrine Biosciences, Inc. | CRF1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
EP3986416A4 (en) | 2019-07-19 | 2023-06-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
WO2021062246A1 (en) | 2019-09-27 | 2021-04-01 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
TW202134241A (zh) | 2019-12-04 | 2021-09-16 | 美商紐羅克里生物科學有限公司 | Crf受體拮抗劑及使用方法 |
JP2023531164A (ja) | 2020-06-10 | 2023-07-21 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト |
JP2023540223A (ja) | 2020-08-26 | 2023-09-22 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crf受容体アンタゴニストおよび使用方法 |
-
2015
- 2015-01-21 EP EP15702917.4A patent/EP3096756A1/en active Pending
- 2015-01-21 RU RU2016133972A patent/RU2718918C2/ru active
- 2015-01-21 IL IL296683A patent/IL296683B2/en unknown
- 2015-01-21 MX MX2016009499A patent/MX2016009499A/es unknown
- 2015-01-21 KR KR1020217015795A patent/KR20210064407A/ko not_active Application Discontinuation
- 2015-01-21 CN CN202010134003.XA patent/CN111228274A/zh active Pending
- 2015-01-21 CA CA3155599A patent/CA3155599A1/en active Pending
- 2015-01-21 KR KR1020167022375A patent/KR102258522B1/ko active IP Right Grant
- 2015-01-21 JP JP2016565135A patent/JP6585625B2/ja active Active
- 2015-01-21 CN CN201580005270.4A patent/CN106102740A/zh active Pending
- 2015-01-21 AU AU2015209452A patent/AU2015209452C1/en active Active
- 2015-01-21 BR BR112016016975-1A patent/BR112016016975B1/pt active IP Right Grant
- 2015-01-21 US US15/113,362 patent/US20170020877A1/en not_active Abandoned
- 2015-01-21 WO PCT/US2015/012315 patent/WO2015112642A1/en active Application Filing
- 2015-01-21 CA CA2936974A patent/CA2936974A1/en active Pending
- 2015-01-21 NZ NZ722122A patent/NZ722122A/en unknown
-
2016
- 2016-07-14 IL IL246783A patent/IL246783B/en unknown
- 2016-07-21 MX MX2021012539A patent/MX2021012539A/es unknown
- 2016-07-21 MX MX2022000080A patent/MX2022000080A/es unknown
-
2018
- 2018-12-20 US US16/227,127 patent/US10905690B2/en active Active
-
2019
- 2019-03-11 JP JP2019043466A patent/JP6936825B2/ja active Active
-
2020
- 2020-06-09 JP JP2020099865A patent/JP7104743B2/ja active Active
- 2020-07-20 AU AU2020207774A patent/AU2020207774B2/en active Active
- 2020-10-20 US US17/074,845 patent/US11730739B2/en active Active
-
2021
- 2021-08-04 US US17/393,553 patent/US11311544B2/en active Active
- 2021-09-29 IL IL286782A patent/IL286782A/en unknown
- 2021-11-12 JP JP2021184620A patent/JP2022010260A/ja active Pending
-
2022
- 2022-10-31 AU AU2022263460A patent/AU2022263460A1/en active Pending
-
2023
- 2023-06-29 IL IL304134A patent/IL304134A/en unknown
- 2023-07-14 US US18/222,011 patent/US20240058342A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11951112B2 (en) | 2021-04-12 | 2024-04-09 | Maxim Masiutin | Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000080A (es) | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. | |
MX2020014300A (es) | Compuestos heterociclicos utiles en el tratamiento de enfermedades. | |
IL287889A (en) | Administration of transgenic t cells for the treatment of central nervous system cancer | |
PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
MX2015016171A (es) | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. | |
PH12015501738A1 (en) | Androgen receptor modulators and uses thereof | |
NI201500093A (es) | Modulador del receptor de andrógenos y usos de este | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
IL272095A (en) | 17-alpha-21-cortexolone diesters for use in the treatment of tumors and as glucocorticoid receptor modulators | |
MX2015011899A (es) | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. | |
SA516370641B1 (ar) | مركبات حلقية غير متجانسة وطرق لاستخدامها | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
MX2017007707A (es) | Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama. | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
EP3145516A4 (en) | Methods and compositions for treating malignancies with dendritic cells | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
HK1248126A1 (zh) | 糖皮質激素受體拮抗劑聯合糖皮質激素用於治療腎上腺功能不全 | |
MY175326A (en) | Product and method for treating diarrhea | |
HK1219896A1 (zh) | 使用 -氨基- -二氧代-呱啶- -基 -異吲哚啉- -二酮治療和控制中樞神經系統癌症的方法和組合物 | |
MX361407B (es) | Formulaciones de liberacion controlada de hidrocortisona. | |
EP3126378A4 (en) | Cardiotonic steroid antagonists and related methods | |
MX2015016603A (es) | Composiciones de corticosteroides. | |
MX2016011706A (es) | Formulaciones de progesterona. | |
AU355858S (en) | Castor brace for ladder |